GW Pharma (GWPH) Reports Q4 Loss of GBP0.05/Share

GW Pharma (NASDAQ: GWPH) reported Q4 EPS of (GBP0.05), versus (GBP0.07) reported last year. Revenue for the quarter came in at GBP5.6 million, versus GBP8.5 million reported last year.

Cash and cash equivalents at 30 September 2015 of £234.9 million ($355.3 million) compared to £164.5 million as at 30 September 2014.

"This last year has seen GW maintain a rapid pace in the progress of our pediatric epilepsy research program, including the start and completion of recruitment of multiple Phase 3 trials for Epidiolex, and the expansion of our expanded access program which has continued to yield promising safety and efficacy data," stated Justin Gover, GW's Chief Executive Officer. "We expect to carry this momentum through 2016 with top-line data from four Epidiolex pivotal trials, our first NDA filing, build-out of our U.S. commercial organization, and ongoing data read-outs from a number of clinical pipeline programs."

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c